Trial | Age | μ |  ± sd | CVp | S 2 fam | S 2 Res | CVg | h2i (se) |
---|---|---|---|---|---|---|---|---|
CHA | 7 | 2.4 | 0.9 | 0.37 | 0.04 | 0.78 | 0.08 | 0.18 (0.06) |
COR | 5.5 | 0.9 | 0.15 | 0.01 | 0.71 | 0.02 | 0.07 (0.06) | |
FOR | 5.2 | 1.0 | 0.19 | 0.01 | 0.98 | 0.02 | 0.04 (0.03) | |
FRI | 3.4 | 1.7 | 0.49 | 0.12 | 2.62 | 0.10 | 0.18 (0.05) | |
MAN | 5.8 | 0.6 | 0.11 |  < 0.01 | 0.37 | 0.01 | 0.04 (0.04) | |
NOC | 5.3 | 1.0 | 0.18 |  < 0.01 | 0.96 | 0.01 | 0.01 (0.03) | |
REB | 5.2 | 1.2 | 0.23 | 0.01 | 1.40 | 0.02 | 0.03 (0.04) | |
CHA | 12 | 2.9 | 0.8 | 0.28 | 0.03 | 0.61 | 0.06 | 0.17 (0.06) |
COR | 2.3 | 1.0 | 0.42 | 0.03 | 0.91 | 0.08 | 0.14 (0.06) | |
FOR | 2.8 | 0.9 | 0.30 | 0.02 | 0.70 | 0.05 | 0.11 (0.05) | |
FRI | 2.5 | 1.1 | 0.45 | 0.07 | 1.18 | 0.10 | 0.21 (0.06) | |
MAN | 3.0 | 0.9 | 0.31 | 0.03 | 0.81 | 0.06 | 0.13 (0.04) | |
NOC | 1.8 | 0.9 | 0.50 | 0.03 | 0.79 | 0.10 | 0.16 (0.05) | |
REB | 2.5 | 1.0 | 0.42 | 0.04 | 1.03 | 0.09 | 0.17 (0.05) | |
FOR | 17 | 2.8 | 0.8 | 0.30 | 0.02 | 0.65 | 0.05 | 0.13 (0.05) |
FRI | Â | 2.5 | 1.0 | 0.40 | 0.05 | 0.96 | 0.09 | 0.20 (0.06) |
MAN | Â | 2.9 | 0.9 | 0.31 | 0.03 | 0.75 | 0.06 | 0.16 (0.05) |